NICE publishes final draft guidance recommending efanesoctocog alfa as an option for treating and preventing bleeding in ...

Cost and evidence gaps remain barriers to approving funding in the NHS for donanemab and lecanemab. Today we’ve published further draft guidance for public consultation that continues to not recommend ...

All NICE products on oesophageal cancer. Includes any guidance and quality standards.

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

NICE publishes final draft guidance recommending efanesoctocog alfa as an option for treating and preventing bleeding in people aged 2 and over with severe haemophilia A.

Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over TA1044 26 February 2025 26 February 2025 Durvalumab with etoposide and either carboplatin or cisplatin for ...

These resources provide access to high quality authoritative evidence and best practice. They are for anyone who works in health and social care and makes decisions about treatments, interventions, or ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

ASSESS-DHT is a European project that aims to increase the adoption of trustworthy and effective digital health technologies (DHTs) across Europe. The project will address the challenges with ...

Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136] Draft guidance Technology appraisal guidance 3 March ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.